Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

Delayed Quote. Delayed  - 08/24 10:00:00 pm
10.02 USD   -5.47%
08/01 ARIAD PHARMACEU : PDL BioPharma Completes Second Tranche Payment Und..
07/28 ARIAD PHARMACEU : beats 2Q profit forecasts
07/28 ARIAD PHARMACEU : Reports Second Quarter and First Half 2016 Financi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ariad Pharmaceuticals, Inc. : ARIAD Announces Completion of Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2013 | 10:20pm CEST

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 per share. In addition, the underwriters have exercised an option to purchase an additional 1,182,893 shares at $19.60 per share to cover over-allotments. The total gross proceeds from the offering are approximately $323 million. Net proceeds to ARIAD are approximately $310 million after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS Investment Bank acted as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. For more information about ARIAD, visit the company's website at www.ariad.com.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
08/11 PDL BIOPHARMA : Completes Second Tranche Payment Under Royalty Transaction with ..
08/08 ARIAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/01 ARIAD PHARMACEUTICALS : PDL BioPharma Completes Second Tranche Payment Under Roy..
07/28 ARIAD PHARMACEUTICALS : beats 2Q profit forecasts
07/28 ARIAD PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regul..
07/28 ARIAD PHARMACEUTICALS : Reports Second Quarter and First Half 2016 Financial Res..
07/22 ARIAD PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders,..
07/07 ARIAD PHARMACEUTICALS : Announces Webcast of Its Annual Stockholders Meeting
07/07 ARIAD PHARMACEUTICALS : Biotechnology Equities Under the Scanner - Exelixis, Nov..
07/05 ARIAD PHARMACEUTICALS : to Webcast Conference Call on Second Quarter 2016 Financ..
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/23 Under New Structure, ARIAD Growth Opportunities May Be Undervalued
08/23 ARIAD Pharmaceuticals Could Be Benefiting From Prescriber Education
08/12 Ariad Is Worth A Look After Q2 Results
08/09 Market At All-Time Highs, September Can Be A Month Of Consolidation
07/29 BIOTECH FORUM DAILY DIGEST : Biotech Tries To Break Through Upward Resistance Le..
Advertisement
Financials ($)
Sales 2016 191 M
EBIT 2016 -119 M
Net income 2016 -55,1 M
Debt 2016 230 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 11,3x
EV / Sales 2017 9,25x
Capitalization 1 931 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 10,4 $
Spread / Average Target 4,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Frank G. Haluska Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..60.32%1 931
AMGEN, INC.5.24%127 850
GILEAD SCIENCES, INC.-20.45%106 233
CELGENE CORPORATION-7.65%85 728
REGENERON PHARMACEUTIC..-25.35%42 671
VERTEX PHARMACEUTICALS..-23.14%23 963
More Results